Ocular Melanoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: OCL022 MIFTS: 40	Ocular Melanoma Categories: Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Ocular Melanoma

MalaCards integrated aliases for Ocular Melanoma:

Name: Ocular Melanoma ⁵³ ⁵⁵

Malignant Melanoma of Eye ⁷³

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases

See all MalaCards categories (disease lists)

External Ids:

UMLS ⁷³ C0558356

Sources

Summaries for Ocular Melanoma

NIH Rare Diseases : ⁵³ Ocular melanoma (OM) is a cancer in pigment-producing cells of the eye called melanocytes. Melanocytes are cells that produce the pigment melanin that colors the skin, hair, and eyes, as well as forms moles. There are four tissues in the eye in which melanoma can develop: the uveal tract (uvea); conjunctiva; eyelid; and orbit. The uvea - the middle layer within the eye - is divided into three main parts: the iris, ciliary body, and choroid. Uveal melanoma, also called intraocular melanoma, is the most common ocular melanoma. Conjunctival melanoma manifests on the surface of the eye and has been increasing in incidence. Eyelid and primary orbital melanoma are the least common variants.

MalaCards based summary : Ocular Melanoma, also known as malignant melanoma of eye, is related to melanoma, uveal and bap1 tumor predisposition syndrome. An important gene associated with Ocular Melanoma is MC1R (Melanocortin 1 Receptor), and among its related pathways/superpathways are Pathways in cancer and NF-kappaB Signaling. The drugs Bevacizumab and Melphalan have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and liver, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Sources

Related Diseases for Ocular Melanoma

Diseases related to Ocular Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 35)

#	Related Disease	Score	Top Affiliating Genes
1	melanoma, uveal	29.6	BAP1 MC1R
2	bap1 tumor predisposition syndrome	11.3
3	melanoma	11.0
4	skin melanoma	10.2
5	peritoneum cancer	10.1	BAP1 BRCA2
6	tumor predisposition syndrome	10.1	BAP1 BRCA2
7	melanoma metastasis	10.1
8	maxillary sinus adenoid cystic carcinoma	10.0	IL2 KIT
9	mast cell neoplasm	10.0	IL2 KIT
10	mucosal melanoma	10.0	IL2 KIT
11	dysgerminoma of ovary	10.0	BRCA2 KIT
12	ocular cancer	10.0	BRCA2 IL2
13	thymus gland disease	10.0	IL2 KIT
14	combined t cell and b cell immunodeficiency	10.0	CIITA IL2
15	leukocyte disease	9.9	IL2 KIT
16	cataract	9.9
17	toxic shock syndrome	9.9	CIITA IL2
18	lymphoma	9.8
19	melanoma, cutaneous malignant 1	9.8	BAP1 KIT MC1R
20	retinal detachment	9.7
21	xeroderma pigmentosum, variant type	9.7
22	budd-chiari syndrome	9.7
23	acute leukemia	9.7
24	b-cell lymphomas	9.7
25	leukemia	9.7
26	dysplastic nevus syndrome	9.7
27	dry eye syndrome	9.7
28	panophthalmitis	9.7
29	peritoneal mesothelioma	9.7
30	liposarcoma	9.7
31	craniopharyngioma	9.7
32	viral infectious disease	9.7
33	syncope	9.7
34	headache	9.7
35	malignant peritoneal mesothelioma	9.7

Graphical network of the top 20 diseases related to Ocular Melanoma:

Sources

Symptoms & Phenotypes for Ocular Melanoma

MGI Mouse Phenotypes related to Ocular Melanoma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hematopoietic system	MP:0005397	9.91	BAP1 BRCA2 CIITA IL2 KIT MC1R
2	endocrine/exocrine gland	MP:0005379	9.88	BAP1 BRCA2 CIITA IL2 KIT SERPINF1
3	immune system	MP:0005387	9.87	BAP1 BRCA2 CIITA IL2 KIT MC1R
4	digestive/alimentary	MP:0005381	9.83	BAP1 BRCA2 IL2 KIT SERPINF1
5	neoplasm	MP:0002006	9.65	BAP1 BRCA2 IL2 KIT MC1R
6	no phenotypic analysis	MP:0003012	9.46	BAP1 IL2 KIT MC1R
7	pigmentation	MP:0001186	9.13	KIT MC1R SERPINF1
8	reproductive system	MP:0005389	9.02	BAP1 BRCA2 IL2 KIT SERPINF1

Sources

Drugs & Therapeutics for Ocular Melanoma

Drugs for Ocular Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Bevacizumab

Approved, Investigational

Phase 3,Phase 2

216974-75-3

Melphalan

Approved

Phase 3,Phase 2

148-82-3

4053 460612

Fotemustine

Experimental, Investigational

Phase 3

Alkylating Agents

Phase 3,Phase 2,Phase 1

Antineoplastic Agents, Alkylating

Phase 3,Phase 2,Phase 1

Immunologic Factors

Phase 3,Phase 2,Phase 1,Not Applicable

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1

Angiogenesis Inhibitors

Phase 3,Phase 2

Angiogenesis Modulating Agents

Phase 3,Phase 2

Vaccines

Phase 3,Phase 2

Liver Extracts

Phase 3,Phase 2,Phase 1

Mitogens

Phase 3,Phase 2

Endothelial Growth Factors

Phase 3,Phase 2

Gemcitabine

Approved

Phase 2

95058-81-4

60750

Cisplatin

Approved

Phase 2

15663-27-1

2767 441203 84093

Tamoxifen

Approved

Phase 2

10540-29-1

2733526

Sunitinib

Approved, Investigational

Phase 2

557795-19-4, 341031-54-7

5329102

Dacarbazine

Approved, Investigational

Phase 2

4342-03-4

5351166

Temozolomide

Approved, Investigational

Phase 2

85622-93-1

5394

Xylometazoline

Approved, Investigational

Phase 2

526-36-3

5709

Lenalidomide

Approved

Phase 2

191732-72-6

216326

Nicotinamide

Approved, Investigational

Phase 2,Phase 1

98-92-0

936

Sorafenib

Approved, Investigational

Phase 2,Phase 1

284461-73-0

216239 406563

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904 498142

Cyclophosphamide

Approved, Investigational

Phase 2,Phase 1

6055-19-2, 50-18-0

2907

Nivolumab

Approved

Phase 2

946414-94-4

Pembrolizumab

Approved

Phase 2,Phase 1

1374853-91-4

Cobalt

Approved, Experimental

Phase 2

7440-48-4

104729

Mesna

Approved, Investigational

Phase 2

3375-50-6

598

Fludarabine

Approved

Phase 2

75607-67-9, 21679-14-1

30751

Aldesleukin

Approved

Phase 2

85898-30-2, 110942-02-4

Vorinostat

Approved, Investigational

Phase 2

149647-78-9

5311

Citric Acid

Approved, Nutraceutical, Vet_approved

Phase 2

77-92-9

311

Niacin

Approved, Investigational, Nutraceutical

Phase 2,Phase 1

59-67-6

938

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 2,Phase 1

59-30-3

6037

Treosulfan

Investigational

Phase 2

299-75-2

9296

Imidazole

Experimental, Investigational

Phase 2

288-32-4

795

Entinostat

Investigational

Phase 2

209783-80-2

Antimetabolites

Phase 2

Antimetabolites, Antineoplastic

Phase 2

Antiviral Agents

Phase 2,Not Applicable

Anti-Infective Agents

Phase 2,Not Applicable

Antineoplastic Agents, Hormonal

Phase 2

Hormone Antagonists

Phase 2

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 2

Estrogen Antagonists

Phase 2

Bone Density Conservation Agents

Phase 2

Estrogen Receptor Modulators

Phase 2

Estrogen Receptor Antagonists

Phase 2

Interventional clinical trials:

(show all 50)

#	Name	Status	NCT ID	Phase	Drugs
1	Collaborative Ocular Melanoma Study (COMS)	Unknown status	NCT00000124	Phase 3
2	Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma	Recruiting	NCT02678572	Phase 3
3	Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma	Not yet recruiting	NCT03172299	Phase 3	Aflibercept Injection;False injection
4	Vaccine Therapy in Treating Patients With Melanoma of the Eye	Terminated	NCT00036816	Phase 3
5	Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma	Terminated	NCT00110123	Phase 3	fotemustine;isolated perfusion
6	Study of Metastatic Ocular Melanoma	Unknown status	NCT00168870	Phase 2	Gemcitabine;Treosulfan
7	Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma	Unknown status	NCT00489944	Phase 2	cisplatin;sunitinib malate;tamoxifen citrate
8	Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye	Unknown status	NCT01217398	Phase 2	temozolomide
9	STA-9090(Ganetespib) in Metastatic Ocular Melanoma	Completed	NCT01200238	Phase 2	STA-9090
10	Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma	Completed	NCT00109005	Phase 2	Revlimid
11	THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease	Completed	NCT01355120	Phase 2	Ipilimumab
12	A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma	Completed	NCT00062933	Phase 2
13	Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery	Completed	NCT01835145	Phase 2	Cabozantinib S-malate;Dacarbazine;Temozolomide
14	Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye	Completed	NCT00020475	Phase 2	gp100 antigen;interleukin-2;MART-1 antigen;Montanide ISA-51
15	Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma	Completed	NCT00003802	Phase 2	pyrazoloacridine
16	Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma	Completed	NCT00085306	Phase 2
17	Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye	Completed	NCT01143402	Phase 2	Dacarbazine;Selumetinib;Temozolomide
18	Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye	Completed	NCT01413191	Phase 2
19	Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye	Completed	NCT00329641	Phase 2	carboplatin;paclitaxel;sorafenib tosylate
20	Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery	Completed	NCT00738361	Phase 2	nab-paclitaxel
21	Taxoprexin® Treatment for Advanced Eye Melanoma	Completed	NCT00244816	Phase 2	Taxoprexin
22	Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma	Recruiting	NCT03528408	Phase 2	Nivolumab;Ipilimumab
23	Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye	Recruiting	NCT02697630	Phase 2	Pembrolizumab;Entinostat
24	Study in Subjects With Small to Medium Primary Choroidal Melanoma	Recruiting	NCT03052127	Phase 1, Phase 2	Light-activated AU-011
25	Nivolumab With or Without Ipilimumab or Relatlimab Before Surgery in Treating Patients With Stage IIIB-IV Melanoma That Can Be Removed by Surgery	Recruiting	NCT02519322	Phase 2
26	Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas	Active, not recruiting	NCT02602756	Phase 2
27	Study With T-cel Receptor Gene Therapy in Metastatic Melanoma	Active, not recruiting	NCT02654821	Phase 1, Phase 2
28	SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver	Active, not recruiting	NCT01473004	Phase 2
29	Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma	Not yet recruiting	NCT03712904	Phase 2
30	An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma	Not yet recruiting	NCT03765229	Phase 2	Entinostat;Pembrolizumab
31	CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301 in Treating Patients With Stage IIB-IV Melanoma	Suspended	NCT02129075	Phase 2
32	Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma	Terminated	NCT01814046	Phase 2	Aldesleukin;Cyclophosphamide;Fludarabine
33	Imatinib in Adult Patients With Metastatic Ocular Melanoma	Terminated	NCT00421317	Phase 2	Imatinib
34	Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma	Terminated	NCT00482911	Phase 2	cyclophosphamide;lenalidomide;sunitinib malate
35	Vorinostat in Treating Patients With Metastatic Melanoma of the Eye	Terminated	NCT01587352	Phase 2	Vorinostat
36	A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma	Terminated	NCT01801358	Phase 1, Phase 2	AEB071;MEK162
37	Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma	Completed	NCT01893099	Phase 1	Sorafenib
38	Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate	Completed	NCT01046487	Phase 1	Imatinib mesylate, Cyclophosphamide (Dosing level 1 );Imatinib mesylate, Cyclophosphamide (Dosing level 2);Imatinib mesylate, Cyclophosphamide (Dosing level 3)
39	Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases	Recruiting	NCT02858869	Phase 1
40	Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566	Active, not recruiting	NCT02315066	Phase 1	PF-04518600;PF-04518600;PF-04518600 plus PF-05082566;PF-04518600 plus PF-05082566
41	The Role of Inflammation in Ocular Tumours	Unknown status	NCT02909517
42	Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone	Completed	NCT00351728
43	Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye	Completed	NCT00952939
44	Cytogenetic Study of Ocular Melanoma	Recruiting	NCT00344799
45	Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy	Recruiting	NCT00346372
46	5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes	Active, not recruiting	NCT02376920
47	Definity for Ultrasound of Intraocular Tumors	Not yet recruiting	NCT01930968
48	Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver	No longer available	NCT01728051		Melphalan
49	Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye	Withdrawn	NCT00621439	Not Applicable	Pegylated Interfon Alpha 2B;Placebo
50	Validation of a Molecular Prognostic Test for Eye Melanoma	Withdrawn	NCT00406120

Search NIH Clinical Center for Ocular Melanoma

Sources

Genetic Tests for Ocular Melanoma

Sources

Anatomical Context for Ocular Melanoma

MalaCards organs/tissues related to Ocular Melanoma:

⁴¹

Eye, Skin, Liver, Endothelial, T Cells, B Cells, Ovary

Sources

Publications for Ocular Melanoma

Articles related to Ocular Melanoma:

(show top 50) (show all 347)

#	Title	Authors	Year
1	Hepatic artery infusion of melphalan in patients with liver metastases from ocular melanoma. ( 29878390 )	Boone B.A....Pingpank J.F.	2018
2	Gamma irradiation of ocular melanoma and lymphoma cells in the presence of gold nanoparticles: inA vitro study. ( 29707895 )	Kanavi M.R....Ahmadieh H.	2018
3	Outcomes of cataract surgery in eyes with ocular melanoma treated with iodine-125 brachytherapy. ( 29703285 )	Bozkurt T.K....Miller K.M.	2018
4	Headache with Aura: A case report of ocular melanoma. ( 30135025 )	Hackett A...Borden N	2018
5	The Patient's Experience of Ocular Melanoma in the US: A Survey of the Ocular Melanoma Foundation. ( 30320098 )	Afshar AR...Damato BE	2018
6	Is Collaborative Ocular Melanoma Study (COMS) still relevant? ( 30249817 )	Honavar SG	2018
7	Ocular Melanoma Recurrence Presenting as Cholestatic Jaundice due to Periampullary Area Metastases. ( 30134646 )	Anastasiadis S...Katsinelos P	2018
8	Ocular melanoma-when you have seen one, you have not seen them all: a clinical outcome study from the Surveillance, Epidemiology and End Results (SEER) database (1973-2012). ( 28115829 )	Mahendraraj K....Chamberlain R.S.	2017
9	Health-related quality of life during trans-arterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for unresectable hepatic metastases from ocular melanoma. ( 28754534 )		2017
10	Comment on &quot;Milham &amp; Stetzer (2016) Tumor-specific frequencies and ocular melanoma.&quot; Electromag Biol Med http://dx.doi.org/10.1080/15368378.2016.1234390. ( 27715332 )		2017
11	PRL-3/PTP4A3 phosphatase regulates integrin I^1 in adhesion structures during migration of human ocular melanoma cells. ( 28284838 )		2017
12	Reproducibility of a Noninvasive System for Eye Positioning and Monitoring in Stereotactic Radiotherapy of Ocular Melanoma. ( 28168935 )		2017
13	Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Ocular Melanoma as a Tool to Predict Metastatic Potential. ( 28448404 )	Wei W...Knopp MV	2017
14	The toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. ( 26655090 )	Yang H....Grossniklaus H.E.	2016
15	EPIDEMIOLOGICAL ANALYSIS OF OCULAR MELANOMA IN UNIVERSITY CLINIC CENTER IN TUZLA, BOSNIA AND HERZEGOVINA. ( 27698609 )	Vodencarevic A.N....Sinanovic M.	2016
16	Imaging of ocular melanoma metastasis. ( 27168029 )	Balasubramanya R....O'Kane P.	2016
17	A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib. ( 27520988 )	Maleka A....Ullenhag G.J.	2016
18	Feasibility of Proton Beam Therapy for Ocular Melanoma Using a Novel 3D Treatment Planning Technique. ( 27084652 )	Hartsell W.F....Pankuch M.	2016
19	Tumor-specific frequencies and ocular melanoma. ( 27552371 )	Milham S....Stetzer D.	2016
20	Metastatic melanoma after 23a88years of primary ocular melanoma. ( 27881589 )		2016
21	Head and neck melanoma (excluding ocular melanoma): United Kingdom National Multidisciplinary Guidelines. ( 27841141 )		2016
22	Overexpression of hepatocyte growth factor and an oncogenic CDK4 variant in mice alters corneal stroma morphology but does not lead to spontaneous ocular melanoma. ( 26731561 )		2016
23	Investigating the dosimetric impact of seed location uncertainties in Collaborative Ocular Melanoma Study-based eye plaques. ( 27475484 )		2016
24	Metastatic ocular melanoma to the liver exhibits infiltrative and nodular growth patterns. ( 27476775 )	Grossniklaus HE...Coupland SE	2016
25	Diffusion-weighted magnetic resonance imaging for predicting and detecting the response of ocular melanoma to proton beam therapy: initial results. ( 25578783 )	Foti P.V....Ettorre G.C.	2015
26	Dynamic contrast-enhanced MRI of ocular melanoma. ( 25714038 )	Jiang X....Erb-Eigner K.	2015
27	Nationwide Incidence of Ocular Melanoma in South Korea by Using the National Cancer Registry Database (1999-2011). ( 26207308 )	Park S.J....Park K.H.	2015
28	Heterogeneous dose calculations for Collaborative Ocular Melanoma Study eye plaques using actual seed configurations and Task Group Report 43 formalism. ( 25533415 )		2015
29	A challenging case of ocular melanoma. ( 26429178 )		2015
30	Low thyroid hormone levels improve survival in murine model for ocular melanoma. ( 25868390 )		2015
31	Metastatic Ocular Melanoma Presenting as a Heart-Compressing Mediastinal Mass. ( 26434443 )		2015
32	Evidence-based integration of selective internal radiation therapy into the management of ocular melanoma liver metastases. ( 25478778 )	Stedman B.	2014
33	Method for verifying the air kerma strength of I-125 plaques for the treatment of ocular melanoma. ( 25207419 )		2014
34	Effects of defining realistic compositions of the ocular melanoma on proton therapy. ( 25599060 )		2014
35	Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist. ( 24697775 )	Martorano LM...Campbell SM	2014
36	Isolated Hepatic Perfusion for Ocular Melanoma Metastasis: Registry Data Suggests a Survival Benefit. ( 24141377 )	Olofsson R....LindnAcr P.	2013
37	Combined surgical resection and radiofrequency ablation as treatment for metastatic ocular melanoma. ( 22766897 )	Derek E....Selby R.	2013
38	Pretherapeutic laboratory findings, extent of metastasis and choice of treatment as prognostic markers in ocular melanoma- a single centre experience. ( 23057648 )	Schicher N....Hoeller C.	2013
39	Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture. ( 23392528 )	Grossniklaus H.E.	2013
40	Ocular melanoma: an overview of the current status. ( 23826405 )	Jovanovic P....Stefanovic V.	2013
41	Ocular melanoma metastasizing to intra-abdominal lymph nodes. ( 23762736 )	Aranovich D....Merhav H.	2013
42	The Collaborative Ocular Melanoma Study, mortality by therapeutic approach, age and tumor size. ( 24069782 )	Lund R.W.	2013
43	Solitary secondary malignant melanoma of clavicle two years after enuclation for ocular melanoma. ( 23424696 )	Tozum H....Graci C.	2013
44	Diffusion-weighted imaging of ocular melanoma. ( 23614974 )		2013
45	Left ventricular metastasis from ocular melanoma: a new, rare, and unusual pathway? ( 23816109 )		2013
46	TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. ( 23799844 )		2013
47	SECONDARY NEUTRON DOSES IN PROTON THERAPY TREATMENTS OF OCULAR MELANOMA AND CRANIOPHARYNGIOMA. ( 24222710 )		2013
48	Baker's Cyst on F-18 FDG PET/CT in a Patient with Ocular Melanoma. ( 23486655 )	CayvarlA+ H....Derebek E.	2012
49	Ocular immune privilege and ocular melanoma: parallel universes or immunological plagiarism? ( 22707951 )	Niederkorn J.Y.	2012
50	Ocular melanoma metastasis to the cervical spine. ( 22245271 )	Shakur S.F....Roitberg B.Z.	2012

Sources

Genes for Ocular Melanoma

Genes related to Ocular Melanoma (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	MC1R	Melanocortin 1 Receptor	Protein Coding	21.3	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	12883368
2	CIITA	Class II Major Histocompatibility Complex Transactivator	Protein Coding	19.89	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	15326139
3	BRCA2	BRCA2, DNA Repair Associated	Protein Coding	19.13	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	12385017
4	BAP1	BRCA1 Associated Protein 1	Protein Coding	16.95	GeneCards inferred via : Publications (show sections)
5	IL2	Interleukin 2	Protein Coding	16.75	GeneCards inferred via : Publications (show sections)
6	KIT	KIT Proto-Oncogene Receptor Tyrosine Kinase	Protein Coding	16.75	GeneCards inferred via : Publications (show sections)
7	SERPINF1	Serpin Family F Member 1	Protein Coding	16.75	GeneCards inferred via : Publications (show sections)

Sources

Variations for Ocular Melanoma

Sources

Expression for Ocular Melanoma

Search GEO for disease gene expression data for Ocular Melanoma.

Sources

Pathways for Ocular Melanoma

Pathways related to Ocular Melanoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Pathways in cancer ³⁷	12.22	BRCA2 IL2 KIT
2	NF-kappaB Signaling ⁴	11.65	CIITA IL2 KIT
3	Innate Lymphoid Cell Differentiation Pathways ⁶⁵	11.16	IL2 KIT
4	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.02	IL2 KIT
5	Melanocyte Development and Pigmentation ⁶⁴	10.24	KIT MC1R

Sources

GO Terms for Ocular Melanoma

Biological processes related to Ocular Melanoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of inflammatory response	GO:0050728	9.32	IL2 SERPINF1
2	hemopoiesis	GO:0030097	9.26	BRCA2 KIT
3	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	9.16	IL2 KIT
4	pigmentation	GO:0043473	8.96	KIT MC1R
5	T cell differentiation	GO:0030217	8.62	IL2 KIT

Molecular functions related to Ocular Melanoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protease binding	GO:0002020	8.62	BRCA2 KIT

Sources

Sources for Ocular Melanoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia